| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 05/26/1998 | US5756503 Analgesics, anesthetics, antiinflammatory agents |
| 05/26/1998 | US5756486 Cyclized nucleotide; viricide |
| 05/26/1998 | US5756483 Pharmaceutical compositions for intranasal administration of apomorphine |
| 05/26/1998 | US5756468 Lyophilized solid drug consists of a compound having botulinum toxicity, stabilizing protein, polysaccharide sugar and thioalkyl compound selected from methionine and cysteine; storage stability |
| 05/26/1998 | US5756329 DNA encoding phenylalanyl tRNA synthetase from Staphylococcus aureus |
| 05/26/1998 | US5756090 Oxygen activatable formulations for disinfection or sterilization |
| 05/26/1998 | CA2056670C Therapeutic agent for glaucoma |
| 05/25/1998 | CA2215929A1 Novel lep |
| 05/22/1998 | WO1998021228A1 Tissue specific expression of retinoblastoma protein |
| 05/22/1998 | WO1998021182A2 Use of cis-δ4 analogs of prostaglandins as ocular hypotensives |
| 05/22/1998 | WO1998021181A2 15-fluoro prostaglandins as ocular hypotensives |
| 05/22/1998 | WO1998020890A1 Morphogen peptide-induced regeneration of sense perceptory tissues |
| 05/22/1998 | WO1998020889A1 Morphogen peptide-induced regeneration of sense perceptory tissues |
| 05/22/1998 | CA2271696A1 Morphogen peptide-induced regeneration of sense perceptory tissues |
| 05/22/1998 | CA2269855A1 15-fluoro prostaglandins as ocular hypotensives |
| 05/22/1998 | CA2269853A1 Use of cis-.delta.4 analogs of prostaglandins as ocular hypotensives |
| 05/20/1998 | EP0843016A2 Staphylococcus FabD (malonylCoA:ACP transacylase) protein |
| 05/20/1998 | EP0843014A2 Tryptophanyl tRNA synthetase |
| 05/20/1998 | EP0843011A2 RsbU-1 derived from Staphylococcus |
| 05/20/1998 | EP0842175A1 Imidazopyridine derivatives |
| 05/20/1998 | EP0842165A1 Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| 05/20/1998 | EP0841937A1 Use of betaglycan to reduce scarring |
| 05/20/1998 | EP0841929A1 Quinolones and their therapeutic use |
| 05/20/1998 | EP0782448A4 Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions |
| 05/20/1998 | CN1182358A Triacetin as transdermal penetration enhancer |
| 05/19/1998 | US5753269 Containing silver sulfadiazine |
| 05/19/1998 | US5753230 Methods and compositions useful for inhibition of angiogenesis |
| 05/14/1998 | WO1998020131A1 Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses |
| 05/14/1998 | WO1998020007A1 Quinolines and their therapeutic use |
| 05/14/1998 | WO1998019999A1 N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity |
| 05/14/1998 | WO1998019712A1 Methods for regulating angiogenesis |
| 05/14/1998 | WO1998019706A1 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
| 05/14/1998 | WO1998019700A1 Treatment of inner ear hair cells |
| 05/14/1998 | WO1998019689A1 Novel coding sequences |
| 05/14/1998 | WO1998019680A1 Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma |
| 05/14/1998 | WO1998019678A1 Improved intraocular irrigating solution containing a polyamine antagonist |
| 05/14/1998 | WO1998019649A2 Methods and compositions for inhibition of angiogenesis |
| 05/14/1998 | CA2271235A1 Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses |
| 05/14/1998 | CA2270922A1 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
| 05/14/1998 | CA2270775A1 Improved intraocular irrigating solution containing a polyamine antagonist |
| 05/14/1998 | CA2270349A1 Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma |
| 05/14/1998 | CA2268126A1 Quinolines and their therapeutic use |
| 05/13/1998 | EP0840616A1 Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease |
| 05/13/1998 | EP0628032B1 Quinazolinone antianginal agents |
| 05/13/1998 | CN1181753A Novel substituted piperazine derivatives having tachyknin receptor antagonists activity |
| 05/13/1998 | CN1181704A Use of glial neurotrophic factor (GDND) for treatment of hearing disorders |
| 05/13/1998 | CN1181703A Controlled release of miotic and mydriatic drugs in the anterior chamber |
| 05/13/1998 | CN1038304C Method for prepn. of growth inhibiting compsn. |
| 05/12/1998 | US5750784 Method for effecting vasodilation with (1,5-inter) aryl prostaglandin derivatives |
| 05/12/1998 | US5750712 Diabetic therapy |
| 05/12/1998 | US5750703 Purity; antihistamines; antiallergens; bronchodilators |
| 05/12/1998 | US5750693 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
| 05/12/1998 | US5750687 Angiotensin converting enzyme inhibitors, neutral endopeptidase inhibitors |
| 05/12/1998 | US5750521 Mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ACE |
| 05/12/1998 | US5750398 Vector, element and method for inhibiting immune recognition |
| 05/12/1998 | US5750387 DNA encoing leucyl TRNA synthetase from staphylococcus aureus |
| 05/07/1998 | WO1998018788A1 Piperazino derivatives as neurokinin antagonists |
| 05/07/1998 | WO1998018786A1 Constrained somatostatin agonists and antagonists |
| 05/07/1998 | WO1998018480A1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 05/07/1998 | WO1998018461A1 Integrin antagonists |
| 05/07/1998 | WO1998009985A3 Anti-inflammatory peptides and uses thereof |
| 05/06/1998 | EP0839910A2 Spo-rel, a Staphylococcus relA/spot homologue |
| 05/06/1998 | EP0839137A1 Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use |
| 05/06/1998 | EP0839042A1 Bacterial inhibition with an oligosaccharide compound |
| 05/06/1998 | EP0839032A1 Hydroxyl ions as unique therapeutic agents and compounds that modulate ions, compounds |
| 05/06/1998 | EP0740652B1 Metalloproteinase inhibitors |
| 05/06/1998 | EP0738270B1 Dihydro pyrazolopyrroles |
| 05/06/1998 | CN1181075A Substituted isoxazoles for the treatment of inflammation |
| 05/06/1998 | CN1181018A 多功能酶 Multifunctional enzyme |
| 05/05/1998 | US5747530 Aromatic dibenzofuran compounds and pharmaceutical/cosmetic compositions comprised thereof |
| 05/05/1998 | US5747514 Metalloproteinase inhibitors |
| 05/05/1998 | US5747458 Plasminogen activator of protease and tripeptides |
| 05/05/1998 | US5747286 Polynucleotides encoding a transcriptional response regulator of Streptococcus pneumoniae |
| 05/05/1998 | US5747061 Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| 04/30/1998 | WO1998017779A1 NOVEL FabH |
| 04/30/1998 | WO1998017645A1 α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS |
| 04/30/1998 | WO1998017249A1 Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum |
| 04/30/1998 | CA2269552A1 Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum |
| 04/30/1998 | CA2268418A1 .alpha.-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
| 04/29/1998 | EP0838523A2 RsbW-1 derived from Staphylococcus |
| 04/29/1998 | EP0838213A1 Use of Krill Enzymes for the Treatment of Dental Plaque |
| 04/29/1998 | EP0837938A2 Use of mp52 or mp121 for treating and preventing diseases of the nervous system |
| 04/29/1998 | EP0837934A1 Human vascular endothelial growth factor 2 |
| 04/29/1998 | EP0837860A1 TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO 3,4-c]-1,2,4-TRIAZOLO 4,3-$g(a)]PYRIDINES |
| 04/29/1998 | EP0837686A2 Use of indigestible oligosaccharides to treat and prevent otitis media in humans |
| 04/29/1998 | CN1180352A Aryl glycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 04/29/1998 | CA2214866A1 Novel spo-rel |
| 04/28/1998 | US5744607 Basic derivatives of glutamic acid and aspartic acid as gastrin or cholecystokinin antagonists |
| 04/28/1998 | US5744451 N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| 04/23/1998 | WO1998016551A2 Variants of vascular endothelial cell growth factor having antagonistic properties |
| 04/23/1998 | WO1998016520A1 The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 04/23/1998 | WO1998016506A1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 04/23/1998 | WO1998016503A2 The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 04/23/1998 | WO1998016243A1 Uses of keratinocyte growth factor-2 |
| 04/23/1998 | WO1998016228A1 USE OF AN H+, K+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS |
| 04/23/1998 | CA2268897A1 The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 04/23/1998 | CA2268895A1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 04/23/1998 | CA2268894A1 The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 04/22/1998 | EP0837130A2 M protein analogue from Streptococcus pneumoniae |
| 04/22/1998 | EP0837073A1 Human mad proteins and uses thereof |